An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A big review paper just compared the popular GLP-1 drugs head-to-head to see which one produces the biggest weight loss. Instead of running one new trial, the researchers pooled results from many existing trials to make indirect comparisons between drugs like semaglutide (sold as Wegovy/Ozempic), liraglutide (Saxenda/Victoza), tirzepatide (a newer drug that hits two targets), and others. The goal was to rank them by how much weight people lost on average and how safe they seemed to be. GLP-1 drugs are synthetic versions of a natural gut hormone that helps control appetite and blood sugar. When this hormone signal is boosted, people usually feel less hungry, get full faster, and their stomachs empty more slowly. Some of these medicines act mainly on the GLP-1 receptor (the cell’s “receiver” for that hormone). Tirzepatide is a bit different because it also activates a GIP receptor (another hormone pathway), so it’s called a “dual agonist” — that just means it stimulates two different receptors. The study the article describes is a meta-analysis, which means the authors combined results from many clinical trials to compare drugs that weren’t all tested directly against each other. That gives a bigger-picture estimate but is not the same as a single large head-to-head trial. According to their pooling, some drugs — particularly semaglutide and tirzepatide at higher doses — tend to produce larger average weight loss than older GLP-1s like liraglutide. The size of the difference varied by dose and by study, and these are averages: individual results can differ a lot. The finding is strongest for short- to mid-term treatment durations used in the trials, typically months to a year. This matters because more people and their doctors are deciding which medication to try for weight loss or diabetes. A clearer sense of which drugs usually produce bigger weight changes helps inform those choices, especially when weighing benefits against costs and side effects. For someone deciding between medicines, a drug that tends to produce larger weight loss might be appealing, but insurance coverage, price, dosing frequency, and personal health history also matter. There are important caveats. Meta-analyses mix trials that differ in design, patient populations, and how strictly they measure outcomes, so the rankings aren’t as definitive as a direct comparison trial. Side effects like nausea, gastrointestinal upset, and, rarely, more serious issues were reported across these drugs; the study’s pooled safety data can mask differences for specific people. Long-term safety and what happens after stopping the drugs are still open questions. Also, not every dose or newer formulation has the same evidence, and some drugs may not be approved or available in every place. Bottom line: pooled trial data suggest semaglutide and tirzepatide typically lead to greater average weight loss than older GLP-1s, but individual results, side effects, availability, and long-term effects should guide decisions rather than rankings alone.
Source: The Hill